Yale Cancer Center (YCC) is pleased to announce the appointment of Marcus Bosenberg, M.D., Ph.D., as Interim Director of the Yale Center for Immuno-Oncology (YCIO). The center was launched in 2018 to build on YCC’s international leadership in immunobiology, cancer immunology, and development of novel cancer immunotherapies. It is a partnership between YCC, Smilow Cancer Hospital and the department of Immunobiology at Yale University.
“Dr. Bosenberg’s dedication to outstanding research and leadership make him an ideal interim director for YCIO,” said Charles Fuchs, M.D., M.P.H., director of YCC and physician-in-chief at Smilow Cancer Hospital. “In his new role, Dr. Bosenberg will collaborate with leadership to design new strategies and advance the scientific activities, core resources, and faculty recruitments for the Center.”
A Professor of Dermatology, Pathology, and Immunobiology, and Director of Yale’s SPORE in Skin Cancer, Bosenberg also serves as Co-Leader of YCC’s Genomics, Genetics, & Epigenetics Research Program.
“I am pleased to accept this opportunity to lead YCIO,” said Bosenberg. “This Center gives us the chance to work more collaboratively and efficiently with our world-renowned scientists and faculty to address scientific questions in Immuno-Oncology.”
Bosenberg replaces inaugural Interim Director Roy S. Herbst, M.D., Ph.D., who led the Center and laid the foundation for this important initiative. “Dr. Herbst’s accomplishments and dedicated efforts have provided an outstanding trajectory for the Center, expanding its presence regionally, nationally, and internationally,” Fuchs said.